TransMedics Q4 revenue $160.8M (+32% YoY); net income $105.4M includes $83.8M tax benefit

TransMedics Group, Inc.

2025-FY EPS reported $4.87 revenue$605,494,000

Q4 revenue $160.8M (+32% YoY); full-year revenue $605.5M (+37% YoY).
Net income $105.4M in Q4 ($2.62 diluted EPS); full-year net income $190.3M ($4.87 diluted EPS). Both include one-time tax benefit from valuation allowance release.
U.S. OCS cases 5,139 in FY2025 (+38% YoY); owned 22 aircraft as of Dec 31, 2025.
FY2026 revenue guidance $727M-$757M, representing 20% to 25% growth over FY2025.
Appointed Giovanni Cecere as CCO, Amanda Sorrento as SVP HR, Matthew Forsyth as SVP GC; FDA approved OCS ENHANCE Heart and DENOVO Lung trials.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.